Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Italy | Malaysia | Pakistan | Peru | Portugal | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: Aesculape CRO Belgium BV
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Candidiasis, Vulvovaginal
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2021-001201-75 |
2021-001201-75 | P2 |
Active, not recruiting |
Candidiasis, Vulvovaginal |
2022-07-13 |